Yunnan Baiyao
Phase 3Small molecule
Yunnan Baiyao is one of 71 small molecule programs targeting Effectiveness. It is currently in Phase 3.
2
Indications
3
Total Trials
2
Active Trials
70
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
76 competitors in Effectiveness
#DrugCompanyPhaseTrials
1Kesimpta
NovartisPhase 3
Actos
TakedaPhase 3
Mounjaro
Eli LillyPhase 3
Elucirem
GGuerbet
Phase 3
Nicotine Free Cigarettes
PfizerPhase 3
Pneumococcal Conjugate Vaccine
NovartisPhase 3
Botulinum Toxin a
GSKPhase 3
Lidocain
BayerPhase 3
Welireg
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 2
Temodar
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Diabetic Foot2 trials
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Yunnan Baiyao. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- PPeking University Third Hospital